Marcela V. Maus, MD, PhD, is a pioneer in the area of adoptive cell therapy. She is the Director of Cellular Immunotherapy at Massachusetts General Hospital (MGH) and an assistant professor at Harvard Medical School. She has extensive experience in gene and cell therapies, in particular in the biology of T cell activation and clinical translation of adoptive immunotherapy, including regulatory and clinical expertise with gene-modified T cells. She has over 15 years of basic laboratory research experience and is board certified in internal medicine, medical oncology and hematology, with particular clinical training in melanoma, myeloma and bone marrow transplants. She has unique expertise in bringing novel cell and gene therapies from the laboratory to the clinic, including the local and federal regulatory processes mandated for clinical translational medicine. Leading multidisciplinary teams of scientists and clinicians, she has successfully opened trials of genetically modified T cells in multiple myeloma, leukemia, mesothelioma, pancreatic and ovarian cancers, as well as glioblastoma multiforme. In her new position at Massachusetts General Hospital Cancer Center, Dr. Maus runs a laboratory that continues to focus on optimal T cell engineering for use as adoptive immunotherapy. Dr. Maus directs the Cellular Immunotherapy Program at MGH, which includes a Cell Therapy clinical unit. In this role, Dr. Maus oversees the clinical and translational research portfolio in Immune Effector cell therapies at MGH.